Cargando…
Testosterone does not affect lower urinary tract symptoms while improving markers of prostatitis in men with benign prostatic hyperplasia: a randomized clinical trial
PURPOSE: Benign Prostatic Hyperplasia (BPH) is a result of prostate inflammation, frequently occurring in metabolic syndrome (MetS). Low testosterone is common in MetS. A randomized clinical trial was designed to evaluate if 24 weeks of testosterone therapy (TTh) in BPH men with MetS and low testost...
Autores principales: | Rastrelli, G., Cipriani, S., Lotti, F., Cellai, I., Comeglio, P., Filippi, S., Boddi, V., Della Camera, P. A., Santi, R., Boni, L., Nesi, G., Serni, S., Gacci, M., Maggi, M., Vignozzi, L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184417/ https://www.ncbi.nlm.nih.gov/pubmed/35298833 http://dx.doi.org/10.1007/s40618-022-01776-9 |
Ejemplares similares
-
Testosterone therapy: a friend or a foe for the aging men with benign prostatic hyperplasia?
por: Rastrelli, Giulia, et al.
Publicado: (2019) -
Benign Prostatic Hyperplasia: A New Metabolic Disease of the Aging Male and Its Correlation with Sexual Dysfunctions
por: Corona, Giovanni, et al.
Publicado: (2014) -
Neuroprotective Effects of Testosterone in the Hypothalamus of an Animal Model of Metabolic Syndrome
por: Sarchielli, Erica, et al.
Publicado: (2021) -
Testosterone positively regulates vagina NO-induced relaxation: an experimental study in rats
por: Cellai, I., et al.
Publicado: (2022) -
Testosterone treatment is associated with reduced adipose tissue dysfunction and nonalcoholic fatty liver disease in obese hypogonadal men
por: Maseroli, E., et al.
Publicado: (2020)